Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Stockspawkon Mar 01, 2019 9:44am

123 Views

Post# 29428103

RE:RE:CEO Purchase

Recent filings
Filing date: 2019-02-27 Transaction: 2019-02-25	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer	Common Shares 15 - Acquisition or disposition under a prospectus	$20,000 +80,000 vol $0.25 each	230,000
Filing date: 2019-02-27 Transaction: 2013-06-10	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer	Warrants 00 - Opening Balance-Initial SEDI Report
Filing date: 2019-02-27 Transaction: 2019-02-25	$ATE Antibe Therapeutics Inc.	Legault, Daniel Marcel 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer	Warrants 15 - Acquisition or disposition under a prospectus	$10,000 +40,000 vol $0.25 each	40,000